Are all Type I human interferons equivalent?

Journal of Viral Hepatitis

Volumn 5, Issue 3, 1998, Pages 143-152

  Foster, G R ^a   Finter, N B ^b  

^a ST MARY S HOSPITAL   (United Kingdom)

^b NONE

Author keywords

Immunomodulation; Interferon; Subtypes

Indexed keywords

ALPHAN1 INTERFERON; INTERFERON; INTRON 2B; RECOMBINANT ALPHA2 INTERFERON; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; CLINICAL TRIAL; DRUG EFFICACY; HEPATITIS; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; NONHUMAN; PRIORITY JOURNAL; REVIEW; VIRUS HEPATITIS; VIRUS INFECTION;

ANIMALS; ANTIBODIES; HUMANS; INTERFERON TYPE I; INTERFERON-ALPHA; INTERFERON-BETA; SIGNAL TRANSDUCTION; VIRUS DISEASES;

EID: 0031830974     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2893.1998.00103.x     Document Type: Review

References (61)

1. Isaacs A, Lindenman J. Virus interference: the interferon. Proc R Soc Med 1957; 147: 258-267.
2. Gresser I, Tovey M, Bandhu T et al. Role of interferon in the pathogenesis of viral disease as demonstrated by the use of anti-interferon serum. Rapid evolution of encephalomyelitis virus infection. J Exp Med 1976; 144: 1305-1315.
3. Wheelock F. Interferon like virus inhibitor induced in human leukocytes by phytohemagglutin. Science 1965; 149: 310-311.
4. Pestka S, Langer T, Zoon K, Samuel C. Interferons and their actions. Annu Rev Biochem 1987; 56: 727-777.
5. Rubinstein M, Levy W, Moschera J et al. Human leukocyte interferon: isolation and characterisation of several molecular forms. Arch Biochem Biophys 1981; 210: 307-318.
6. Diaz M, Allen G. Nomenclature of the human interferon proteins. J Interferon Res 1994; 14: 223-226.
7. Hiscott J, Cantell K, Weissman C. Differential expression of human interferon genes. Nucl Acid Res 1984; 12: 3727-3746.
8. Hauptman R, Sweetly P. A novel class of human Type I interferons. Nucl Acid Res 1985; 13: 4739-4749.
9. Finter N. Why are there so many subtypes of alpha interferons? J Interferon Res 1991; 185-194.
10. Li X, Leung S, Kerr I, Stark G. Functional domains of STAT2 required for preassociation with the alpha interferon receptor and for signalling. Mol Cell Biol 1997; 17: 2048-2056.
11. Muller M, Ibelgaufts H, Kerr I. Interferon response pathways - a paradigm for cytokine signalling. J Viral Hep 1994; 1: 78-86.
12. Foster G. Interferons in host defense. Semin Liver Dis 1998 (in press).
13. Uze G, Lutfalla G, Mogensen K. Alpha and beta interferons and their receptor and their friends and relatives. J Interferon Cytokine Res 1995; 15: 3-26.
14. Platanias L, Uddin S, Yetter A, Xiao-Jian S, White M. The Type I interferon receptor mediates tyrosine phosphorylation of insulin receptor substrate 2. J Biol Chem 1996; 271: 278-282.
15. Uddin S, Yenush L, Xiao-Jian S, Sweet M, White M, Platanias L. Interferon alpha engages the insulin receptor substrate-1 to associate with the phosphatidylinositol 3′ kinase. J Biol Chem 1995; 270: 15938-15941.
16. David M, Petricon E, Benjamin C, Pine R, Weber M, Larner A. Requirement for MAP kinase activity in interferon alpha and beta stimulated gene expression through STAT proteins. Science 1995; 269: 1721-1723.
17. Petricion E, Ito S, Williams B et al. Antiproliferative action of interferon alpha requires components of T-cell-receptor signalling. Nature 1997; 390: 629-632.
18. Pellegrini S, John J, Shearer M, Kerr I, Stark G. Use of a selectable marker regulated by alpha interferon to obtain mutations in the signalling pathway. Mol Cell Biol 1989; 9: 4605-4612.
19. Foster G, Rodrigues O, Ghouze F et al. Different relative activities of human cell derived interferon alpha subtypes: IFN alpha 8 has very high antiviral potency. J Interferon Cytokine Res 1996; 16: 1027-1033.
20. Sandhya Rani M, Foster G, Leung S, Leaman D, Stark G, Ransohoff R. Characterisation of b-R1, a gene that is selectively induced by IFN beta compared with interferon alpha. J Biol Chem 1996; 271: 22878-22884.
21. Sen G, Ransohoff R. Interferon-induced antiviral action and their regulation. Adv Virus Res 1993; 42: 57-102.
22. Pestka S, Evinger M, Maeda S, Rehder E, Familletti P, Kelder B. Biological properties of natural and recombinant interferons. Tex Rep Biol Med 1981; 41: 31-36.
23. Evinger M, Rubinstein M, Pestka S. Growth inhibitory and anti viral activity of purified leucocyte interferon. Ann NY Acad Sci 1980; 350: 399-404.
24. Fish E, Banerjee K, Stebbing N. Human leukocyte interferon subtypes have different antiproliferative and antiviral activities on human cells. Biochem Biophys Res Commun 1983; 112: 537-546.
25. Rehberg E, Kelder B, Hoal E, Pestka S. Specific molecular activities of recombinant and hybrid leukocyte interferons. J Biol Chem 1982; 257: 11497-11502.
26. Sperber S, Gocke D, Haberzettl C, Kuk R, Schwartz B, Pestka S. Anti-HIV activity of recombinant and hybrid species of interferon alpha. J Interferon Res 1992; 12: 363-368.
27. Sperber S, Hunger S, Schwartz B, Pestka S. Anti-rhinoviral activity of recombinant and hybrid species of interferon alpha. Antiviral Res 1993; 22: 121-129.
28. Week P, Appeson S, May L, Stebbing N. Comparison of the antiviral activities of various cloned human interferon alpha subtypes in mammalian cell cultures. J Gen Virol 1981; 57: 233-242.
29. Herberman R, Ortaldo J, Bonnard G. Augmentation by interferon of human natural and antibody dependent cell-mediated cytotoxicity. Nature 1979; 277: 221.
30. Ortaldo J, Herbermann R, Harvey C et al. A species of human interferon that lacks the ability to boost natural killer cell activity. Proc Natl Acad Sci USA 1984; 81: 4926-4929.
31. von Hoegen P. Synergistic role of Type I interferons in the induction of protective cytotoxic T lymphocytes. Immunol Lett 1995; 47: 157-162.
32. Mueller U, Steinhoff U, Reis L, Hemmi S, Zinkernagel R, Aguet M. Targetted disruption of the murine type I interferon receptor gene. Science 1993; 264: 1918-1921.
33. Harris H, Gill T. Expression of class I transplantation antigens. Transplantation 1986; 42: 109-117.
34. Fleisher T, Attallah A, Tosato G, Blaese M, Green W. Interferon-mediated inhibition of human polyclonal immunoglobulin synthesis. J Immunol 1982; 129: 1099-1103.
35. Neubauer R, Goldstein L, Rabin H, Stebbing N. Stimulation of in vitro immunoglobulin production by interferon alpha. J Immunol 1985; 134: 299-306.
36. Hibbert L, Brand C, Leadbeater L, Thomas H, Foster G. IFN alpha 8 activation of human B cells. Immunology 1996; 89 (S1): OZ269.
37. Rhodes J, Ivanyi J, Cozens P. Antigen presentation by human monocytes: effects of modifying major histocompatability complex class II antigen expression and interleukin 1 production by using recombinant interferons and corticosteroids. Eur J Immunol 1986; 16: 370-374.
38. Rogge L, Barberis-Maino L, Biffi M et al. Selective expression of an interleukin-12 receptor component by human T helper 1 cells. J Exp Med 1997; 185: 825-831.
39. Paty D, Li D, UBC MS/MRI Study group. Interferon beta 1b is effective in relapsing-remitting multiple sclerosis. MRI analysis of a multicentre, randomised, double-blind, placebo controlled trial. Neurology 1993; 43: 662-667.
40. Jiang H, Milo R, Swoveland P, Johnson K, Panitch H, Dhib-Jalbut S. Interferon beta 1b reduced interferon gamma induced antigen presenting capacity of human glial and B cells. J Immunol 1995; 61: 17-25.
41. Dhib-Jalbut S, Jiang H, Xia Q, Blatt L, Johnson K, Hilt D. Comparative effects of interferon consensus 1, interferon-a2a and interferon beta 1b on HLA expression and lymphoproliferation: a preclinical model for treatment of multiple sclerosis. J Interferon Res 1996; 16: 195-200.
42. Romeo G, Fiorucci G, Rossi G. Interferons in cell growth and development. Trends Genet Sci 1989; 5: 19-23.
43. Petrucci M, Mandelli F, Dianzani F, Valtuena J, eds. Lymphoblastoid alpha interferon. Clinical Use of Interferon in Haematology, Vol. 7. London: Current Medical Literature Ltd; 1995: 48-56.
44. Wadler S, Schwartz E. Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review. Cancer Res 1990; 50: 3473-3486.
45. Gresser I, Maury P, Brouty-Boye D. Mechanism of the antitumour effect of interferon in mice. Nature 1972; 239: 167-168.
46. Beasley R, Hwang L, Lin C, Chien C. Hepatocellular carcinoma and hepatitis B virus - a prospective study of 22,707 men in Taiwan. Lancet 1981; ii: 1129-1133.
47. Foster G, Goldin R, Main J, Murray-Lyon I, Hargreaves S, Thomas H. The management of chronic hepatitis C: clinical audit of a biopsy based management algorithm. Br Med J 1997; 315: 453-458.
48. Oon C. Long term survival following treatment of hepatocellular carcinoma in Singapore: evaluation of Wellferon in the prophylaxis of high risk pre-cancerous conditions. Cancer Chemother Pharmacol 1992; 31: S137-S142.
49. Nishiguchi S, Kuroli T, Nakatani S et al. Randomised trial of effects of interferon alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346: 1051-1055.
50. Fattovich G, Giustina G, Degos F et al. Effectiveness of interferon alpha on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. J Hepatol 1997; 27: 201-205.
51. von Wussow P, Freund M, Block B, Diedrich H, Poliwoda H, Deicher H. Clinical significance of anti-IFN alpha antibody titres during interferon therapy. Lancet 1989; ii: 635-636.
52. Antonelli G, Dianzani F. Antibodies to interferon alpha in patients. Arch Virol 1993; 8: 271.
53. Steis R, Smith H, Urba W et al. Loss of interferon antibodies during prolonged continuous interferon a2a therapy in hairy cell leukaemia. Blood 1991; 77: 792-799.
54. von Wussow, Jakschies D, Freund M et al. Treatment of anti-recombinant interferon-alpha 2 antibody positive CML patients with natural interferon-alpha. Br J Haematol 1991; 78: 210-216.
55. Antonelli G, Gianella G, Pistello M et al. Clinical significance of recombinant interferon alpha 2 neutralising antibodies in hepatitis patients. J Interferon Res 1994; 14: 211-213.
56. McKenna R, Oberg K. Antibodies to interferon a in treated cancer patients: incidence and significance. J Interferon Cytokine Res 1997; 17: 141-143.
57. Brand C, Leadbetter L, Bellati G, Marotta F, Ideo G. Antibodies developing against a single recombinant interferon protein may neutralise many other interferon-α subtypes. J Interferon Res 1993; 13: 121-125.
58. Antonelli G, Current M, Turriziani O, Dianzani F. Neutralising antibodies to interferon-α: relative frequency in patients treated with different interferon preparations. J Infec Dis 1991; 163: 882-885.
59. Palleroni A, Aglione A, Labow M et al. Preclinical evaluation of interferon immunogenicity. J Interferon Res 1994; 14 (S1): 5128.
60. Mousalli J, Opolon P, Poynard T. Management of hepatitis C. JViral Hep 1998; 5: 73-82.
61. Lok A. Treatment of chronic hepatitis B. J Viral Hep 1993; 1: 91-101.